No significant difference was found in age, sex distribution, BM blasts, FAB classification, frequent AML mutations (FLT3-ITD, NPM1, IDH1/IDH2, RUNX1, MLL-PTD, NRAS/KRAS, TET2, WT1 and TP53), or relapse rate between two subgroups. This evidence concerns the gene KMT2A and acute myeloid leukemia.